Page last updated: 2024-08-26

arsenic and idelalisib

arsenic has been researched along with idelalisib in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aguilera-Montilla, N; Amigo-Jiménez, I; Bailón, E; García-Marco, JA; García-Pardo, A; Terol, MJ1
Bashash, D; Dadashi, M; Ghaffari, SH; Momeny, M; Safa, M; Safaroghli-Azar, A1

Other Studies

2 other study(ies) available for arsenic and idelalisib

ArticleYear
Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
    Oncotarget, 2015, Dec-29, Volume: 6, Issue:42

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Communication; Cell Line; Class I Phosphatidylinositol 3-Kinases; Coculture Techniques; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mesenchymal Stem Cells; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; NF-kappa B; Oxides; Phosphorylation; Protein Kinase C beta; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Purines; Quinazolinones; RNA Interference; Signal Transduction; STAT3 Transcription Factor; Staurosporine; Time Factors; Transfection; Tumor Cells, Cultured; Tumor Microenvironment; Up-Regulation

2015
Anti-tumor activity of PI3K-δ inhibitor in hematologic malignant cells: Shedding new light on resistance to Idelalisib.
    The international journal of biochemistry & cell biology, 2017, Volume: 85

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation; Humans; Inhibitor of Apoptosis Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Oxides; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Purines; Quinazolinones; Survivin

2017